Asieris Pharmaceuticals Revolutionizes Cervical Precancer Treatment with CEVIRA® Approval in China Asieris Pharmaceuticals announces the approval of CEVIRA®, a groundbreaking non-invasive therapy for cervical precancerous lesions in China.

Asieris Pharmaceuticals Revolutionizes Cervical Precancer Treatment with CEVIRA® Approval in China #China #Shanghai #Cervical_Cancer #Asieris_Pharmaceuticals #CEVIRA

Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China Asieris Pharmaceuticals has achieved a significant milestone with the approval of CEVIRA in China, marking the first non-invasive therapy for cervical precancerous lesions.

Asieris Receives Approval for CEVIRA as the First Non-Invasive Therapy for Cervical Precancerous Lesions in China #China #N/A #Photocure #CEVIRA #Asieris

Asieris Receives Regulatory Approval for CEVIRA in China, Pioneering Non-Invasive Treatment for Cervical Lesions Asieris Pharmaceuticals celebrates the approval of CEVIRA, the first non-invasive therapy for cervical precancerous lesions in China, transforming treatment approaches.

Asieris Receives Regulatory Approval for CEVIRA in China, Pioneering Non-Invasive Treatment for Cervical Lesions #China #Nanjing #Asieris_Pharmaceuticals #Photocure_ASA #CEVIRA

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe Asieris Pharmaceuticals communicates that the EMA has accepted the application for CEVIRA, a new photodynamic therapy for HSIL. Discover what this means for treatment options in Europe.

Asieris Announces EMA Acceptance for CEVIRA Marketing Authorization in Europe #Norway #Oslo #Photocure #CEVIRA #Asieris